<DOC>
	<DOC>NCT02186171</DOC>
	<brief_summary>This is a phase 3 multicenter study to compare the efficacy and safety of Romosozumab (AMG 785) with placebo in men with osteoporosis.</brief_summary>
	<brief_title>A Double-blind Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis</brief_title>
	<detailed_description>This is a multicenter, randomized, double-blind, placebo-controlled study in approximately 225 men with osteoporosis. The study is designed to evaluate if treatment with romosozumab once a month for 12 months compared with placebo is effective in increasing BMD at the lumbar spine. Additionally, the study will assess the effect of treatment with romosozumab for 12 months compared with placebo on BMD at the femoral neck and total hip.</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Must be ambulatory male subjects ≥ 55 years to ≤ 90 years of age Must have a BMD T score ≤ 2.50 at the spine or hip, or BMD T score ≤ 1.50 at the spine or hip and a history of fragility nonvertebral fracture or vertebral facture. A BMD T score ≤ 3.50 at the hip, History of hip fracture Severe metabolic bone diseases Significant laboratory abnormalities Recent treatment with agents affecting bone metabolism</criteria>
	<gender>Male</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Osteoporosis in men</keyword>
</DOC>